RxDoctor Payments Data

Ryan Roubion, MD

Orthopaedic Surgery · Metairie, LANPI 1154862456

Payments from drug & device makers

What this record shows

The money is spread across several categories — education (44.7%), grants and food and beverage — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Smith+Nephew at 42.5% of the total. Reporting peaked in 2022 at $32,467 and has fallen 96.1% since, to $1,257 in 2025. Among orthopaedic surgery clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$47,891in general payments, 2019–2025

Across 102 payments — averaging $469.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$20K
  • Arthrex$20K
  • Stryker$5K
  • ALON Medical Technology$1K
  • Biorez, Inc.$257
  • Acera Surgical, Inc.$176
  • plus $781 from 18 others

What the payments were for

  • Grants$20,00042%
  • Travel & lodging$1,9794%
  • Food & beverage$4,5129%
  • Education$21,40045%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$47,891 in reported general payments places this provider in the 90th percentile of 286 orthopaedic surgery providers in Louisiana.

See all orthopaedic surgery providers in Louisiana

Medicare billing

Part B allowed, 2024
$19,845
Medicare patients
53
Services billed
287

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Methylprednisolone29$210
Celecoxib15$199
Meloxicam74$159
Gabapentin15$99
Cyclobenzaprine Hcl27$82
Tramadol Hcl16$47

Paid to pharmacies, not to this prescriber.

Other orthopaedic surgery in Metairie

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →